Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of February 15, 2021, the Board of Directors of Bioanalytical Systems, Inc. (the "Company") elected John Gregory Beattie, age 54, Chief Operating Officer of the Company.

Mr. Beattie previously held Corporate Vice President positions at Charles River Laboratories, a contract research organization, where he led business units within all three of their segments. In these roles, Mr. Beattie was responsible for driving operational performance. There are no arrangements or understandings between Mr. Beattie and any other persons pursuant to which he was elected as an officer and Mr. Beattie has no family relationships with any other director or executive officer of the Company.

Under the terms of Mr. Beattie's employment, he is entitled to receive an annual base salary of $300,000 and a discretionary annual incentive bonus which is tied to company performance metrics and individual achievements. Mr. Beattie is also entitled to participate in the Company's benefit plans and programs provided to Company executives generally, subject to eligibility requirements and the other terms and conditions of those plans and programs. On February 15, 2021, Mr. Beattie received a grant of 15,000 restricted shares, which vest on the second anniversary of the grant date, subject to relevant vesting parameters.

Item 7.01 Regulation FD Disclosure.

On February 11, 2021, the Company issued a press release regarding Mr. Beattie's election. A copy of the press release is furnished as Exhibit 99.1 to this report. Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit No.   Description
  99.1          Press Release, dated February 11, 2021.

© Edgar Online, source Glimpses